Project Grant HT94252410088
Award Date
5/1/24
Completion Date
4/30/27
Dollars Obligated
$807K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...
This $439,912 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Provincial Health Services Authority, operating as BC Cancer, a major Canadian healthcare organization specializing in cancer research, treatment, and prevention. The grant aims to "HARNESSING THE IMMUNE RESPONSE IN EXCEPTIONALLY LONG-TERM SURVIVORS TO DEVELOP NOVEL THERAPEUTICS", leveraging BC Cancer's expertise...
The federal Project Grant award of $438,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research conducted by the Provincial Health Services Authority in Canada, operating under the name BC Cancer, to decode and target genomic instability in pediatric osteosarcoma. The project, with a period of performance from September 30, 2023 to September 29, 2025, aims to develop innovative solutions for cancer treatment,...
The U.S. Defense Health Agency awarded a $109,895 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Provincial Health Services Authority (operating as BC Cancer) in Canada. The grant is for the purpose of "DEVELOPING FIRST-IN-KIND PRECLINICAL MODELS OF PRIMARY TESTICULAR LYMPHOMA" over a 2-year period from September 1, 2024 to August 31, 2026. As a prominent Canadian healthcare organization specializing in cancer research, treatment, and...
This Project Grant award of $508,747.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports the "THE OVARIAN CANCER OBSERVATORY: PREVENTION, IMPACT, AND LEARNING FROM OPPORTUNISTIC SALPINGECTOMY" research project conducted by the Provincial Health Services Authority (operating as BC Cancer) in Canada. Through this multi-year (Sep 1, 2023 - Aug 31, 2027) grant, BC Cancer will perform biomedical research to develop...
The $1,050,767 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University Health Network (UHN) to investigate therapeutic targeting of genomic instability in triple negative breast cancer. The research will be conducted at UHN's location in Ottawa, Ontario over a 3-year period from September 2023 to September 2026. This funding supports UHN's ongoing biomedical and clinical research...
This federal Project Grant award of $426,154 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of British Columbia (UBC) to investigate immunological landscapes in neuroendocrine prostate cancer. The goal is to develop strategies for enhancing the efficacy of immunotherapy. UBC, a prominent public research university in Canada, will leverage its advanced research capabilities and expertise in...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
The federal Project Grant award of $1,477,615.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. This research, conducted by the University of British Columbia, aims to transform healthcare for military service members, veterans, and the broader public through innovative and...